Micron Pharmaceuticals Limited - Due diligence report

A 360° intelligence report on Micron Pharmaceuticals Limited: trust score, financial health, credit view, compliance, directors, growth and …

2005-09-30 Mumbai, Maharashtra Active Unlisted Active Compliant
Connect MCP
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Micron Pharmaceuticals Limited — 360° Intelligence Report

Generated from MCA filings & public records
70/100
Trust Score
Moderate

Micron Pharmaceuticals Limited is assessed as Moderate with a Trust Score of 70/100. Micron Pharmaceuticals Limited is an active public limited indian non-government company incorporated in 2005, operating in the Healthcare sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and low financial risk profile.

Report generated on 22 Nov 2026 from the latest processed filings. Micron Pharmaceuticals Limited snapshot & full profile →

Overall Assessment CautionWeakNeutralGoodStrong Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
70/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
58/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
80/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
55/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreModerate
55/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
90/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
70/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 0 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 55/100 Moderate
  • Negative operating earnings - debt service depends on external support.
  • No open charges - unencumbered balance sheet.
  • Profitable - internal accruals available.

Charges position: 0 open ( 48.0 cr ) · 0 satisfied ( 12.5 cr ).

Compliance Score: 58/100 Moderate
  • Company status is Active as per MCA.
  • Last balance sheet is for Mar 2024 - filings overdue.
  • Litigation present in 1 court forum(s).
  • 1 auditor resignation(s) filed - latest: SWETA GANDHI & CO. on 2021-04-01.
05

Director Intelligence

Stability score: 55/100
NameDIN / PANDesignationAppointedTenureDIN status
PUSHPAK NARESH RANKA 01234567 Director 01/04/2018 6 yrs Approved
VINOD OTARMAL RANKA 01234567 Director 01/04/2018 6 yrs Approved
MAHESH KUMAR OTARMAL RANKA 01234567 Director 01/04/2018 6 yrs Approved
NARESH OTARMAL JAIN 01234567 Director 01/04/2018 6 yrs Approved
  • 4 directors on the board.
  • MAHESH KUMAR OTARMAL RANKA has DIN status "Deactivated due to non-filing of DIR-3 KYC".
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
1
Capital events
-

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Veritas Bioventions Pvt Ltd Associate Company 74.00%

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 90 · Distress 70
Growth signals & trust indicators
Revenue acceleration: +38% over 4 year(s).
Latest year revenue grew 1.42.
Profit expanded 2.1x year-on-year.
Operating for 21+ years.
Distress signals & risk flags
Outside liabilities up 24% in a year.
Statutory filings appear overdue.
Compliance score is weak (58/100).
1 auditor resignation(s) on record - review the stated reasons.
1 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence65/100
Review suggested
Suitability as a supplier / customer counterparty.
  • Check the compliance flags before onboarding.
  • 2 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment63/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance gaps should be priced into terms.
Investor view82/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 3 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management churn warrants questions.
09

MCA Filings & Events Timeline

Latest 9 events
30 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
17 Jun 2016
Director ceased
MANISH JAYANTILAL JAIN
Director ceased
MAHESH KUMAR OTARMAL RANKA
13 Jun 2016
Director appointed
PUSHPAK NARESH RANKA (Director)
Director appointed
VINOD OTARMAL RANKA (Director)
30 Sep 2005
Incorporated
Registered with Roc Mumbai
Director appointed
MAHESH KUMAR OTARMAL RANKA (Director)
Director appointed
NARESH OTARMAL JAIN (Director)
10

Key Observations

Auto-generated from the data above
Revenue grew 0.86 over the last 4 financial year(s).
Net worth is positive.
4 active director(s) / partner(s); review board churn before relying on management continuity.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Chimera Biotech Private Limited U24304DL2019PTC349632 New Delhi, Delhi, India
Team Tony Private Limited U33201GJ2021PTC120261 Surendra Nagar, Gujarat, India
Opto Electronics Private Limited U55101KA1976PTC002944 Banglaore, Karnataka, India
Aasabi Machinery Private Limited U29295MH1994PTC083030 Dist Thane, Maharashtra, India
Franko - India - Drugs Formulations Private Limited U24299RJ2019PTC064070 Jaipur, Rajasthan, India
Mediline Engineers U33200DL2021PTC383678 Delhi, Delhi, India
Sidd Life Sciences Private Limited U33112TN1989PTC017930 Chennai, Tamil Nadu, India
Medi-Bed (India) Private Limited U33112DL1997PTC088646 New Delhi, Delhi, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Micron Pharmaceuticals Limited before audits and certifications: compliance score 58/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Micron Pharmaceuticals Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 55/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 90/100, margin trends, ownership structure and peer set for Micron Pharmaceuticals Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Review suggested. Trust score 70/100, distress signals and MSME payment-delay disclosures - know whether Micron Pharmaceuticals Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Micron Pharmaceuticals Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Micron Pharmaceuticals Limited an active company?

Micron Pharmaceuticals Limited has MCA status “Active” with a compliance score of 58/100 (Moderate).

Is Micron Pharmaceuticals Limited financially healthy?

Micron Pharmaceuticals Limited has a Financial Health Score of 80/100 (Low Risk) based on its filed financial statements.

Should I do business with Micron Pharmaceuticals Limited?

Its overall Trust Score is 70/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Micron Pharmaceuticals Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 4 active director(s) are on record.

Does Micron Pharmaceuticals Limited have loans or charges against its assets?

No charges are registered against this company - an unencumbered balance sheet.

Is Micron Pharmaceuticals Limited up to date with its ROC filings?

Last balance sheet is for Mar 2024 - filings overdue. Overall compliance score: 58/100 (Moderate).

Is it risky to lend to Micron Pharmaceuticals Limited?

Its Credit Risk Score is 55/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.